文献速递糖尿病

恩格列净心血管结局在不同社会人口亚组中一致:EMPRISE真实世界分析

Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study.
PubMed 文献 · Diabetes Care · 2026-09-21

基于2014-2020年Medicare索赔数据,倾向评分匹配后比较≥65岁2型糖尿病患者启用恩格列净与DPP4i或GLP-1RA的心血管结局。恩格列净较DPP4i降低MACE、HHF和全因死亡风险,较GLP-1RA降低HHF风险,社会人口亚组间无效应异质性,基线CVD者绝对获益更大。

要点

  • 恩格列净较DPP4i降低MACE(HR 0.77)、HHF(HR 0.72)和全因死亡(HR 0.66)风险。
  • 恩格列净较GLP-1RA降低HHF风险(HR 0.88),绝对获益在基线CVD者中更大。
  • 社会人口因素亚组间无效应异质性,≥75岁患者绝对获益呈数值趋势更高。

核心结论

  • 恩格列净较DPP4i和GLP-1RA降低心血管事件,社会人口及CVD亚组间效应一致,基线CVD者绝对获益更高。

研究设计与样本

  • 基于2014-2020年Medicare索赔数据的回顾性队列,倾向评分匹配≥65岁2型糖尿病启用恩格列净者与DPP4i或GLP-1RA使用者。

主要发现

  • 恩格列净较DPP4i:MACE HR 0.77(99.9% CI 0.69-0.85),IRD -10.3(-14.1至-6.4)。
  • 恩格列净较DPP4i:HHF HR 0.72(0.67-0.79),IRD -18.3(-22.9至-13.6)。
  • 恩格列净较DPP4i:ACM HR 0.66(0.57-0.76),IRD -8.6(-11.4至-5.8)。
  • 恩格列净较GLP-1RA:HHF HR 0.88(0.81-0.95),IRD -6.9(-10.8至-3.1)。
  • 基线CVD在IRD尺度上对全部结局存在效应异质性,HR尺度仅HHF存在;社会人口因素无效应异质性。

临床怎么用

  • ≥65岁2型糖尿病患者选用恩格列净可期望一致的心血管获益,不受社会人口因素影响。
  • 基线已有CVD者使用恩格列净的绝对获益更大,可优先考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to explore the heterogeneity of empagliflozin treatment effects on major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality (ACM) across sociodemographic and cardiovascular disease (CVD) subgroups of adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Using 2014-2020 Medicare claims data, we examined rates of MACE (e.g., composite myocardial infarction, stroke, all-cause mortality [ACM]), HHF, and ACM among propensity score-matched individuals aged ≥65 years with T2D initiating empagliflozin compared with those prescribed dipeptidyl peptidase-4 inhibitors (DPP4is) and those prescribed GLP-1 receptor agonists (GLP-1RAs). We calculated hazard ratios (HRs) and incidence rate differences (IRDs) overall and by age, sex, race or ethnicity, socioeconomic factors, and baseline CVD. RESULTS: Empagliflozin was associated with decreased risk of MACE (HR 0.77, 99.9% CI [0.69, 0.85]; IRD = -10.3 [-14.1, -6.4]); HHF (HR 0.72 [0.67, 0.79]; IRD = -18.3 [-22.9, -13.6]); and ACM (HR 0.66 [0.57, 0.76]; IRD = -8.6 [-11.4, -5.8]) compared with DPP4is. Effect heterogeneity by baseline CVD was present across all outcomes on the IRD scale but only for HHF on the HR scale. Empagliflozin was also associated with decreased risk of HHF (HR 0.88 [0.81, 0.95]; IRD = -6.9 [-10.8, -3.1]) versus GLP-1RAs, with effect heterogeneity by baseline CVD on the IRD scale. No effect heterogeneity was observed by sociodemographic factors, although a numeric trend suggested greater absolute benefit in patients aged ≥75 years compared with those aged 65-74 years. CONCLUSIONS: Empagliflozin reduced cardiovascular events across sociodemographic and CVD subgroups compared with both DPP4is and GLP-1RAs, with higher absolute benefits observed in those with prevalent CVD.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Cromer SJ, Tesfaye H, Cho H, et al. Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study. Diabetes Care. 2026. PMID: 42765974. doi:10.2337/dca26-0039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。